Collonges sous Salève, France

Pascale Gaillard

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 8 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Serono S. a., Merck Patent Gmbh, Laboratoires Serono S.a.. Active years: 2007-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pascale Gaillard. Retrieved from https://idiyas.com/inventor/pascale-gaillard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 62.5

 

 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 29(Granted Patents)


Location History:

  • St. Julien-en-Genevois, FR (2007 - 2008)
  • St-Julien-en-Genevois, FR (2008 - 2010)
  • Saint-Julien-en-genevois, FR (2010)
  • Collonges Sous Sal{grave over ())}{grave over (})}ve, FR (2011)
  • Collonges sous Saleve, FR (2010 - 2013)
  • Collonges-Sous-Saléve, FR (2013)
  • Collonge-sous-Saleve, FR (2015)
  • Collongues sous Salève, FR (2015)
  • Collonges sous Salève, FR (2014 - 2021)

Company Filing History:


Years Active: 2007-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
BTK Inhibitors
PI3K Inhibitors
JNK Modulators
Heteroaryl Compounds
Tricyclic Derivatives
Quinoxaline Inhibitors
Pyrazine Derivatives
Benzothiazole Formulations
CNS Disorders
Scleroderma Treatment
Protein Kinase Modulators
Piperazine Compounds
16 patents (USPTO):Explore Patents

Title: Pascale Gaillard: Innovator in BTK Inhibitors

Introduction

Pascale Gaillard is a prominent inventor based in Collonges sous Salève, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for Bruton's tyrosine kinase (BTK). With a total of 16 patents to her name, her work has garnered attention in the scientific community.

Latest Patents

Among her latest patents are "Heteroaryl compounds as BTK inhibitors and uses thereof - Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors." Another notable patent is "Heteroaryl compounds as BTK inhibitors and uses thereof - The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors." These innovations highlight her focus on developing effective therapeutic agents.

Career Highlights

Pascale has worked with notable companies in the pharmaceutical industry, including Merck Serono S.A. and Merck Patent GmbH. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research in her field.

Collaborations

Throughout her career, Pascale has collaborated with esteemed colleagues such as Jean-Pierre Gotteland and Vincent Pomel. These partnerships have further enhanced her research and development efforts.

Conclusion

Pascale Gaillard's contributions to the field of BTK inhibitors exemplify her dedication to innovation in pharmaceuticals. Her extensive patent portfolio and collaborations with industry leaders underscore her impact on medical research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…